Treatment of airway inflammation in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 6, 1996, Pages 452-456

  Konstan, Michael W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; FISH OIL; GLUCOCORTICOID; IBUPROFEN; LEUKOCYTE ELASTASE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PIROXICAM; PREDNISONE; PROTEINASE INHIBITOR;

AGE; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PNEUMONIA; QUALITY OF LIFE; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CHEMOTAXIS, LEUKOCYTE; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FISH OILS; GLUCOCORTICOIDS; HUMANS; IBUPROFEN; INFLAMMATION; LEUKOCYTE ELASTASE; NEUTROPHILS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PIROXICAM; PNEUMONIA; PREDNISONE; PROTEASE INHIBITORS; QUALITY OF LIFE;

EID: 0030276193     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Davis PB, Drumm M, Konstan MW: Cystic fibrosis: state of the art. Am J Respir Crit Care Med, in press.
2. Konstan MW, Berger M: Infection and inflammation in the lung in cystic fibrosis. In Cystic Fibrosis. Edited by Davis PB. New York: Marcel Dekker;1993:219-276.
3. Kahn TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
4. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD: Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995, 310:1571-1572.
5. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD: Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with CF. Pediatr Pulmonol 1996, 21:267-275.
6. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M: Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine IL-10 which is down-regulated In cystic fibrosis. Am J Respir Cell Mol Biol 1995, 13:257-261.
7. DiMango E, Zar HJ, Bryan R, Prince A: Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995, 96:2204-2210.
8. Mizgerd JP, Kobzik L, Warner AE, Brain JD: Effects of sodium concentration on human neutrophil bactericidal functions. Am J Physiol 1995, 269 (Lung Cell Mol Physiol 13):L388-L393.
9. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB: Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996, 271:64-67.
10. Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85:229-236.
11. Birrer P, McElvaney NG, Rüdeberg A, Wirz Sommer C, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG: Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994, 150:207-213.
12. Konstan MW, Hilliard KA, Norvell TM, Berger M: Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994, 150:448-454.
13. Balough K, McCubbin M, Weinberger M, Smits W, Aherns R, Fick R: The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995, 20:63-70.
14. Cantin A: Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med 1995, 151:939-941.
15. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR: Alternate-day prednisone reduces morbidity and improves pulmonary function In cystic fibrosis. Lancet 1985, ii(8457):686-688.
16. Donati MA, Haver K, Gerson W, Klein M, McLaughlin FJ, Wohl MEB: Long-term alternate day prednisone therapy In cystic fibrosis. Pediatr Pulmonol 1990, (suppl 5):277.
17. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV: A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995, 126:515-523.
18. Rosenstein BJ, Eigen H: Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991, 87:245-246.
19. Greally P, Hussain MJ, Vergani D, Price JF: Interleukin-1α, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994, 71:35-39.
20. Schiotz PO, Jorgensen M, Winge Flensborg E, Faero O, Husby S, Hoiby N, Vidar Jacobsen S, Nielsen H, Svehag SE: Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: a longitudinal study of immune complex activity and inflammatory response In sputum solphase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. Influence of local steroid treatment Acta Paediatr Scand 1983, 72:283-287.
21. Bisgaard H, Nielsen KG, Skov M, Mosfeldt E, Bjerre B, Pedersen SS, Hoiby N, Koch C: Inhaled steroid treatment of CF patients with chronic Pseudomonas aeruginosa (P.a.) lung Infection. Pediatr Pulmonol 1994, (suppl 10):289.
22. Van Haren EHJ, Lammers JWJ, Festen J, Heijerman HGM, Groot CAR, van Herwaarden CLA: The effects of the inhaled corticosterold budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995, 89:209-214.
23. Nikolaizik WH, Schoni MH: Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996, 128:271-274.
24. Wojtczak HA, Wagener JS, Accurso FJ: Inhaled steroid effects on airway inflammation in children with cystic fibrosis. Israel J Med Sci 1996, 32(suppl):S189.
25. Balfour-Lynn IM, Klein NJ, Dinwiddie R: Trial of inhaled corticosteroids (fluticasone propionate) in children with cystic fibrosis. Israel J Med Sci 1996, 32(suppl):S190.
26. Konstan MW, Vargo KM, Davis PB: Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginoso in a rat model of chronic pulmonary infection: implications for anti-inflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990, 141:186-192.
27. 4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993, 148:896-901.
28. Konstan MW, Hilliard KA, Davis PB: Effect of ibuprofen on neutrophil (PMN) delivery to mucosal surfaces. Pediatr Pulmonol 1989, (suppl 4):152-153.
29. Konstan MW, Hoppel CL, Chai B, Davis PB: Ibuprofen in children with cystic fibrosis: pharmacokinetlcs and adverse effects. J Pediatr 1991, 118:956-964.
30. Konstan MW, Byard PJ, Hoppel CL, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
31. Sordelli DO, Macri CN, Maillie AJ, Cerquetti MC: A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Int J Immunopathol Pharmacol 1994, 7:109-117.
32. Cheung ATW, Moss RB, Leong AB, Novick WJ: Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effect of pentoxifylline on neutrophil influx. J Med Primatol 1992, 21:357-362.
33. Aronoff SC, Quinn FJ Jr, Carpenter LS, Novick WJ Jr: Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr 1994, 125:992-997.
34. Henderson WR Jr, Astley SJ, McCready MM, Kushmerick P, Casey S, Becker JW, Ramsey BW: Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 1994, 124:400-408.
35. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG: Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 1991, 337:392-394.
36. Berger M, Konstan M, Hilliard J, and the CF Prolastin Study Group: Aerosolized prolastin (α1-protease inhibitor) in CF. Pediatr Pulmonol 1995, 20:421.
37. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG: Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-B levels on the respiratory epithelial surface by aerosolizatlon of recombinant secretory leukoprotease Inhibitor. J Clin Invest 1992, 90:1296-1301.
38. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG: Pharmacokinetlcs of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993, 148:1056-1060.
39. Winklhofer-Roob BM, Schlegel-Haueter SE, Khoschsorur G, Van't Hof MA, Suter S, Shmerlimg DH: Neutrophil elastase/α1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral β-carotene supplementation. Pediatr Res 1996, 40:130-134.
40. Rouhm JH, Buhl R, McElvaney NG, Borok Z, Crystal RG: Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993, 75:2419-2424.
41. Konstan MW: Evolving anti-inflammatory therapy in cystic fibrosis. In New Insights Into Cystic Fibrosis. Edited by Ramsey BW, Hodson ME. Califon, NJ: Gardiner-Caldwell SynerMed; 1995:7-11.
42. Ramsey BW: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335:179-188.